Form 4: Axon Director Sells 100 Shares in Pre-Planned Transaction

Axon Enterprise Director Jeri Williams sold 100 shares of common stock for approximately $55,065 in a pre-scheduled transaction.

Summary

• Jeri Williams, a Director of Axon Enterprise, Inc. (AXON), sold a total of 100 shares of common stock.
• The sales occurred on December 4, 2025.
• 65 shares were sold at a weighted average price of $550.2209 per share.
• 35 shares were sold at a weighted average price of $551.3929 per share.
• The total value of the shares sold was approximately $55,065.
• Following these transactions, Jeri Williams directly owns 1,316 shares of Axon common stock.
• The transactions were executed pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 5

Explanation: The sale of shares by a director is generally a neutral event when executed under a pre-arranged 10b5-1 plan, as it indicates a scheduled liquidity event rather than a reaction to new company developments. The amount sold is also relatively small compared to the director's remaining holdings.

Positives

• The transaction was pre-planned under a Rule 10b5-1(c) plan, indicating it was not a reactive sale based on new, non-public information.

Negatives

• A director selling shares, even if pre-planned, reduces their direct ownership in the company.

Risks

• No specific risks are mentioned in the filing. The sale itself, while pre-planned, could be perceived by some investors as a minor signal of reduced insider confidence, though this is mitigated by the 10b5-1 plan.

Future Outlook

The filing does not contain any forward-looking statements or guidance.

Industry Context

This Form 4 filing is a routine disclosure of an insider stock transaction and does not provide information related to broader industry trends or competitors.

Stakeholder Impact

• Shareholders: The sale of a small number of shares by a director under a 10b5-1 plan is unlikely to have a significant impact on shareholders. It's a routine disclosure.
• Employees, Customers, Suppliers, Creditors: No direct impact on these stakeholders is indicated by this filing.

Key Dates

Recommendation

The filing reports a routine, pre-planned sale of a relatively small number of shares by a director under a 10b5-1 plan. This type of transaction typically does not signal a change in the company's fundamental outlook or warrant a change in investment recommendation. Investors should hold their position and consider broader company performance and market conditions.

Keywords

Axon Enterprise, AXON, Form 4, Insider Trading, Director Sale, Jeri Williams, Stock Transaction, 10b5-1 Plan, Common Stock